ID   AK1D1_HUMAN             Reviewed;         326 AA.
AC   P51857; A1L4P6; A8K060; B4DPN3; B4DPN8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   15-MAR-2017, entry version 147.
DE   RecName: Full=3-oxo-5-beta-steroid 4-dehydrogenase;
DE            EC=1.3.1.3 {ECO:0000269|PubMed:18407998};
DE   AltName: Full=Aldo-keto reductase family 1 member D1;
DE   AltName: Full=Delta(4)-3-ketosteroid 5-beta-reductase;
DE   AltName: Full=Delta(4)-3-oxosteroid 5-beta-reductase;
GN   Name=AKR1D1; Synonyms=SRD5B1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7508385; DOI=10.1111/j.1432-1033.1994.tb19947.x;
RA   Kondo K.-H., Kai M.-H., Setoguchi Y., Eggertsen G., Sjoeblom P.,
RA   Setoguchi T., Okuda K., Bjoerkhem I.;
RT   "Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-
RT   reductase and substrate specificity of the expressed enzyme.";
RL   Eur. J. Biochem. 219:357-363(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], CHARACTERIZATION, FUNCTION, TISSUE
RP   SPECIFICITY, AND SUBSTRATE SPECIFICITY.
RX   PubMed=11342103; DOI=10.1016/S0167-4781(00)00278-5;
RA   Charbonneau A., The V.L.;
RT   "Genomic organization of a human 5beta-reductase and its pseudogene
RT   and substrate selectivity of the expressed enzyme.";
RL   Biochim. Biophys. Acta 1517:228-235(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Liver, and Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH NADP.
RX   PubMed=18624455; DOI=10.1021/bi800572s;
RA   Faucher F., Cantin L., Luu-The V., Labrie F., Breton R.;
RT   "The crystal structure of human Delta4-3-ketosteroid 5beta-reductase
RT   defines the functional role of the residues of the catalytic tetrad in
RT   the steroid double bond reduction mechanism.";
RL   Biochemistry 47:8261-8270(2008).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH NADP.
RX   PubMed=19075558; DOI=10.1021/bi801276h;
RA   Faucher F., Cantin L., Luu-The V., Labrie F., Breton R.;
RT   "Crystal structures of human Delta4-3-ketosteroid 5beta-reductase
RT   (AKR1D1) reveal the presence of an alternative binding site
RT   responsible for substrate inhibition.";
RL   Biochemistry 47:13537-13546(2008).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) IN COMPLEXES WITH NADP;
RP   TESTOSTERONE; PROGESTERONE AND CORTISONE, MUTAGENESIS OF TYR-58 AND
RP   GLU-120, CATALYTIC ACTIVITY, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=18407998; DOI=10.1074/jbc.M801778200;
RA   Di Costanzo L., Drury J.E., Penning T.M., Christianson D.W.;
RT   "Crystal structure of human liver delta(4)-3-ketosteroid 5beta-
RT   reductase (AKR1D1) and implications for substrate binding and
RT   catalysis.";
RL   J. Biol. Chem. 283:16830-16839(2008).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) IN COMPLEX WITH NADP.
RX   PubMed=19515843; DOI=10.1074/jbc.C109.016931;
RA   Drury J.E., Di Costanzo L., Penning T.M., Christianson D.W.;
RT   "Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride
RT   and structure of the enzyme-inhibitor complex.";
RL   J. Biol. Chem. 284:19786-19790(2009).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH NADP.
RX   PubMed=18848863; DOI=10.1016/j.mce.2008.09.013;
RA   Di Costanzo L., Drury J.E., Christianson D.W., Penning T.M.;
RT   "Structure and catalytic mechanism of human steroid 5beta-reductase
RT   (AKR1D1).";
RL   Mol. Cell. Endocrinol. 301:191-198(2009).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS) IN COMPLEX WITH NADP AND
RP   TESTOSTERONE.
RX   PubMed=22437839; DOI=10.1074/jbc.M111.338780;
RA   Chen M., Drury J.E., Christianson D.W., Penning T.M.;
RT   "Conversion of human steroid 5beta-reductase (AKR1D1) into 3beta-
RT   hydroxysteroid dehydrogenase by single point mutation E120H: example
RT   of perfect enzyme engineering.";
RL   J. Biol. Chem. 287:16609-16622(2012).
RN   [16]
RP   VARIANTS CBAS2 PHE-106 AND LEU-198.
RX   PubMed=12970144; DOI=10.1136/gut.52.10.1494;
RA   Lemonde H.A., Custard E.J., Bouquet J., Duran M., Overmars H.,
RA   Scambler P.J., Clayton P.T.;
RT   "Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid
RT   5beta-reductase, in hepatitis and liver failure in infancy.";
RL   Gut 52:1494-1499(2003).
RN   [17]
RP   VARIANTS CBAS2 ARG-133 AND CYS-261.
RX   PubMed=15030995; DOI=10.1016/j.jhep.2003.12.024;
RA   Gonzales E., Cresteil D., Baussan C., Dabadie A., Gerhardt M.F.,
RA   Jacquemin E.;
RT   "SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-
RT   reductase deficiency: evidence for primary genetic defect.";
RL   J. Hepatol. 40:716-718(2004).
CC   -!- FUNCTION: Efficiently catalyzes the reduction of progesterone,
CC       androstenedione, 17-alpha-hydroxyprogesterone and testosterone to
CC       5-beta-reduced metabolites. The bile acid intermediates 7-
CC       alpha,12-alpha-dihydroxy-4-cholesten-3-one and 7-alpha-hydroxy-4-
CC       cholesten-3-one can also act as substrates.
CC       {ECO:0000269|PubMed:11342103}.
CC   -!- CATALYTIC ACTIVITY: 5-beta-cholestan-3-one + NADP(+) = cholest-4-
CC       en-3-one + NADPH. {ECO:0000269|PubMed:18407998}.
CC   -!- CATALYTIC ACTIVITY: 17,21-dihydroxy-5-beta-pregnane-3,11,20-trione
CC       + NADP(+) = cortisone + NADPH. {ECO:0000269|PubMed:18407998}.
CC   -!- ENZYME REGULATION: Subject to inhibition by high substrate
CC       concentrations. Inhibited by testosterone concentrations above 10
CC       uM. {ECO:0000269|PubMed:18407998}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.7 uM for testosterone {ECO:0000269|PubMed:18407998};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P51857-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P51857-2; Sequence=VSP_042901;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P51857-3; Sequence=VSP_042913;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver. Expressed in testis
CC       and weakly in colon. {ECO:0000269|PubMed:11342103}.
CC   -!- DISEASE: Congenital bile acid synthesis defect 2 (CBAS2)
CC       [MIM:235555]: A condition characterized by jaundice, intrahepatic
CC       cholestasis and hepatic failure. Patients with this liver disease
CC       show absence or low levels of chenodeoxycholic acid and cholic
CC       acid in plasma and urine. {ECO:0000269|PubMed:12970144,
CC       ECO:0000269|PubMed:15030995}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the aldo/keto reductase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z28339; CAA82193.1; -; mRNA.
DR   EMBL; AF283659; AAG39381.1; -; Genomic_DNA.
DR   EMBL; AF283651; AAG39381.1; JOINED; Genomic_DNA.
DR   EMBL; AF283652; AAG39381.1; JOINED; Genomic_DNA.
DR   EMBL; AF283653; AAG39381.1; JOINED; Genomic_DNA.
DR   EMBL; AF283654; AAG39381.1; JOINED; Genomic_DNA.
DR   EMBL; AF283655; AAG39381.1; JOINED; Genomic_DNA.
DR   EMBL; AF283656; AAG39381.1; JOINED; Genomic_DNA.
DR   EMBL; AF283657; AAG39381.1; JOINED; Genomic_DNA.
DR   EMBL; AF283658; AAG39381.1; JOINED; Genomic_DNA.
DR   EMBL; AK289425; BAF82114.1; -; mRNA.
DR   EMBL; AK298421; BAG60645.1; -; mRNA.
DR   EMBL; AK298428; BAG60650.1; -; mRNA.
DR   EMBL; AC009263; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC024082; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC083867; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236950; EAL24049.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83881.1; -; Genomic_DNA.
DR   EMBL; BC130625; AAI30626.1; -; mRNA.
DR   EMBL; BC130627; AAI30628.1; -; mRNA.
DR   CCDS; CCDS55169.1; -. [P51857-2]
DR   CCDS; CCDS55170.1; -. [P51857-3]
DR   CCDS; CCDS5846.1; -. [P51857-1]
DR   PIR; S41120; S41120.
DR   RefSeq; NP_001177835.1; NM_001190906.1. [P51857-3]
DR   RefSeq; NP_001177836.1; NM_001190907.1. [P51857-2]
DR   RefSeq; NP_005980.1; NM_005989.3. [P51857-1]
DR   UniGene; Hs.201667; -.
DR   UniGene; Hs.740214; -.
DR   PDB; 3BUR; X-ray; 1.62 A; A/B=1-326.
DR   PDB; 3BUV; X-ray; 1.35 A; A/B=1-326.
DR   PDB; 3BV7; X-ray; 1.79 A; A/B=1-326.
DR   PDB; 3CAQ; X-ray; 2.20 A; A/B=1-326.
DR   PDB; 3CAS; X-ray; 2.00 A; A/B=1-326.
DR   PDB; 3CAV; X-ray; 1.90 A; A/B=1-326.
DR   PDB; 3CMF; X-ray; 1.90 A; A/B=1-326.
DR   PDB; 3COT; X-ray; 2.03 A; A/B=1-326.
DR   PDB; 3DOP; X-ray; 2.00 A; A/B=1-326.
DR   PDB; 3G1R; X-ray; 1.70 A; A/B=1-326.
DR   PDB; 3UZW; X-ray; 1.89 A; A/B=1-326.
DR   PDB; 3UZX; X-ray; 1.64 A; A/B=1-326.
DR   PDB; 3UZY; X-ray; 1.83 A; A/B=1-326.
DR   PDB; 3UZZ; X-ray; 1.82 A; A/B=1-326.
DR   PDBsum; 3BUR; -.
DR   PDBsum; 3BUV; -.
DR   PDBsum; 3BV7; -.
DR   PDBsum; 3CAQ; -.
DR   PDBsum; 3CAS; -.
DR   PDBsum; 3CAV; -.
DR   PDBsum; 3CMF; -.
DR   PDBsum; 3COT; -.
DR   PDBsum; 3DOP; -.
DR   PDBsum; 3G1R; -.
DR   PDBsum; 3UZW; -.
DR   PDBsum; 3UZX; -.
DR   PDBsum; 3UZY; -.
DR   PDBsum; 3UZZ; -.
DR   ProteinModelPortal; P51857; -.
DR   SMR; P51857; -.
DR   BioGrid; 112596; 8.
DR   STRING; 9606.ENSP00000242375; -.
DR   DrugBank; DB07447; 5-beta-DIHYDROTESTOSTERONE.
DR   DrugBank; DB00548; Azelaic Acid.
DR   DrugBank; DB01216; Finasteride.
DR   SwissLipids; SLP:000001272; -. [P51857-1]
DR   iPTMnet; P51857; -.
DR   PhosphoSitePlus; P51857; -.
DR   BioMuta; AKR1D1; -.
DR   DMDM; 1703007; -.
DR   EPD; P51857; -.
DR   MaxQB; P51857; -.
DR   PaxDb; P51857; -.
DR   PeptideAtlas; P51857; -.
DR   PRIDE; P51857; -.
DR   DNASU; 6718; -.
DR   Ensembl; ENST00000242375; ENSP00000242375; ENSG00000122787. [P51857-1]
DR   Ensembl; ENST00000411726; ENSP00000402374; ENSG00000122787. [P51857-3]
DR   Ensembl; ENST00000432161; ENSP00000389197; ENSG00000122787. [P51857-2]
DR   GeneID; 6718; -.
DR   KEGG; hsa:6718; -.
DR   UCSC; uc003vtz.4; human. [P51857-1]
DR   CTD; 6718; -.
DR   DisGeNET; 6718; -.
DR   GeneCards; AKR1D1; -.
DR   HGNC; HGNC:388; AKR1D1.
DR   HPA; HPA057002; -.
DR   MalaCards; AKR1D1; -.
DR   MIM; 235555; phenotype.
DR   MIM; 604741; gene.
DR   neXtProt; NX_P51857; -.
DR   OpenTargets; ENSG00000122787; -.
DR   Orphanet; 79303; Congenital bile acid synthesis defect type 2.
DR   PharmGKB; PA24681; -.
DR   eggNOG; KOG1577; Eukaryota.
DR   eggNOG; COG0656; LUCA.
DR   GeneTree; ENSGT00760000119041; -.
DR   HOGENOM; HOG000250272; -.
DR   HOVERGEN; HBG000020; -.
DR   InParanoid; P51857; -.
DR   KO; K00251; -.
DR   OMA; QLLMWRD; -.
DR   OrthoDB; EOG091G0D69; -.
DR   PhylomeDB; P51857; -.
DR   TreeFam; TF106492; -.
DR   BRENDA; 1.3.1.3; 2681.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193775; Synthesis of bile acids and bile salts via 24-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   SABIO-RK; P51857; -.
DR   EvolutionaryTrace; P51857; -.
DR   GenomeRNAi; 6718; -.
DR   PRO; PR:P51857; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000122787; -.
DR   CleanEx; HS_AKR1D1; -.
DR   ExpressionAtlas; P51857; baseline and differential.
DR   Genevisible; P51857; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0004033; F:aldo-keto reductase (NADP) activity; TAS:Reactome.
DR   GO; GO:0047787; F:delta4-3-oxosteroid 5beta-reductase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005496; F:steroid binding; TAS:UniProtKB.
DR   GO; GO:0008209; P:androgen metabolic process; IDA:UniProtKB.
DR   GO; GO:0006699; P:bile acid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0030573; P:bile acid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0008207; P:C21-steroid hormone metabolic process; IDA:UniProtKB.
DR   GO; GO:0006707; P:cholesterol catabolic process; IDA:UniProtKB.
DR   GO; GO:0007586; P:digestion; IDA:UniProtKB.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   CDD; cd06660; Aldo_ket_red; 1.
DR   Gene3D; 3.20.20.100; -; 1.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR020471; Aldo/keto_reductase.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   PANTHER; PTHR11732; PTHR11732; 1.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PIRSF; PIRSF000097; AKR; 1.
DR   PRINTS; PR00069; ALDKETRDTASE.
DR   SUPFAM; SSF51430; SSF51430; 1.
DR   PROSITE; PS00798; ALDOKETO_REDUCTASE_1; 1.
DR   PROSITE; PS00062; ALDOKETO_REDUCTASE_2; 1.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Bile acid catabolism;
KW   Complete proteome; Cytoplasm; Disease mutation;
KW   Intrahepatic cholestasis; Lipid degradation; Lipid metabolism; NADP;
KW   Oxidoreductase; Reference proteome; Steroid metabolism.
FT   CHAIN         1    326       3-oxo-5-beta-steroid 4-dehydrogenase.
FT                                /FTId=PRO_0000124669.
FT   NP_BIND      22     26       NADP. {ECO:0000269|PubMed:18624455,
FT                                ECO:0000269|PubMed:18848863,
FT                                ECO:0000269|PubMed:19075558,
FT                                ECO:0000269|PubMed:19515843,
FT                                ECO:0000269|PubMed:22437839}.
FT   NP_BIND     169    170       NADP. {ECO:0000269|PubMed:18624455,
FT                                ECO:0000269|PubMed:18848863,
FT                                ECO:0000269|PubMed:19075558,
FT                                ECO:0000269|PubMed:19515843,
FT                                ECO:0000269|PubMed:22437839}.
FT   NP_BIND     219    224       NADP. {ECO:0000269|PubMed:18624455,
FT                                ECO:0000269|PubMed:18848863,
FT                                ECO:0000269|PubMed:19075558,
FT                                ECO:0000269|PubMed:19515843,
FT                                ECO:0000269|PubMed:22437839}.
FT   NP_BIND     273    283       NADP. {ECO:0000269|PubMed:18624455,
FT                                ECO:0000269|PubMed:18848863,
FT                                ECO:0000269|PubMed:19075558,
FT                                ECO:0000269|PubMed:19515843,
FT                                ECO:0000269|PubMed:22437839}.
FT   ACT_SITE     58     58       Proton donor.
FT   BINDING      26     26       Substrate.
FT   BINDING      53     53       NADP. {ECO:0000269|PubMed:18624455,
FT                                ECO:0000269|PubMed:18848863,
FT                                ECO:0000269|PubMed:19075558,
FT                                ECO:0000269|PubMed:19515843,
FT                                ECO:0000269|PubMed:22437839}.
FT   BINDING      58     58       Substrate.
FT   BINDING      89     89       Substrate.
FT   BINDING     120    120       Substrate.
FT   BINDING     132    132       Substrate.
FT   BINDING     193    193       NADP. {ECO:0000269|PubMed:18624455,
FT                                ECO:0000269|PubMed:18848863,
FT                                ECO:0000269|PubMed:19075558,
FT                                ECO:0000269|PubMed:19515843,
FT                                ECO:0000269|PubMed:22437839}.
FT   BINDING     230    230       Substrate.
FT   VAR_SEQ     153    193       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042913.
FT   VAR_SEQ     286    326       IFDFSLTEEEMKDIEALNKNVRFVELLMWRDHPEYPFHDEY
FT                                -> VARSS (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042901.
FT   VARIANT     106    106       L -> F (in CBAS2; dbSNP:rs121918343).
FT                                {ECO:0000269|PubMed:12970144}.
FT                                /FTId=VAR_033007.
FT   VARIANT     133    133       P -> R (in CBAS2; dbSNP:rs267606649).
FT                                {ECO:0000269|PubMed:15030995}.
FT                                /FTId=VAR_044430.
FT   VARIANT     198    198       P -> L (in CBAS2; dbSNP:rs121918342).
FT                                {ECO:0000269|PubMed:12970144}.
FT                                /FTId=VAR_033008.
FT   VARIANT     261    261       R -> C (in CBAS2; dbSNP:rs267606650).
FT                                {ECO:0000269|PubMed:15030995}.
FT                                /FTId=VAR_044431.
FT   MUTAGEN      58     58       Y->A: Loss of activity.
FT                                {ECO:0000269|PubMed:18407998}.
FT   MUTAGEN     120    120       E->A: Loss of activity.
FT                                {ECO:0000269|PubMed:18407998}.
FT   CONFLICT     14     14       D -> V (in Ref. 3; BAF82114).
FT                                {ECO:0000305}.
FT   STRAND        9     11       {ECO:0000244|PDB:3BUV}.
FT   STRAND       17     21       {ECO:0000244|PDB:3BUV}.
FT   TURN         29     31       {ECO:0000244|PDB:3BUV}.
FT   HELIX        36     47       {ECO:0000244|PDB:3BUV}.
FT   STRAND       51     53       {ECO:0000244|PDB:3BUV}.
FT   HELIX        56     58       {ECO:0000244|PDB:3BUV}.
FT   HELIX        61     73       {ECO:0000244|PDB:3BUV}.
FT   HELIX        79     81       {ECO:0000244|PDB:3BUV}.
FT   STRAND       83     88       {ECO:0000244|PDB:3BUV}.
FT   HELIX        90     92       {ECO:0000244|PDB:3BUV}.
FT   HELIX        95     97       {ECO:0000244|PDB:3BUV}.
FT   HELIX        98    109       {ECO:0000244|PDB:3BUV}.
FT   STRAND      114    120       {ECO:0000244|PDB:3BUV}.
FT   HELIX       147    159       {ECO:0000244|PDB:3BUV}.
FT   STRAND      162    170       {ECO:0000244|PDB:3BUV}.
FT   HELIX       173    180       {ECO:0000244|PDB:3BUV}.
FT   STRAND      191    195       {ECO:0000244|PDB:3BUV}.
FT   HELIX       203    211       {ECO:0000244|PDB:3BUV}.
FT   STRAND      215    220       {ECO:0000244|PDB:3BUV}.
FT   TURN        228    230       {ECO:0000244|PDB:3BUV}.
FT   HELIX       238    240       {ECO:0000244|PDB:3BUV}.
FT   HELIX       242    250       {ECO:0000244|PDB:3BUV}.
FT   HELIX       255    265       {ECO:0000244|PDB:3BUV}.
FT   HELIX       277    284       {ECO:0000244|PDB:3BUV}.
FT   HELIX       293    300       {ECO:0000244|PDB:3BUV}.
FT   HELIX       312    314       {ECO:0000244|PDB:3BUV}.
FT   STRAND      321    324       {ECO:0000244|PDB:3UZX}.
SQ   SEQUENCE   326 AA;  37377 MW;  1FE02B95398A0A6F CRC64;
     MDLSAASHRI PLSDGNSIPI IGLGTYSEPK STPKGACATS VKVAIDTGYR HIDGAYIYQN
     EHEVGEAIRE KIAEGKVRRE DIFYCGKLWA TNHVPEMVRP TLERTLRVLQ LDYVDLYIIE
     VPMAFKPGDE IYPRDENGKW LYHKSNLCAT WEAMEACKDA GLVKSLGVSN FNRRQLELIL
     NKPGLKHKPV SNQVECHPYF TQPKLLKFCQ QHDIVITAYS PLGTSRNPIW VNVSSPPLLK
     DALLNSLGKR YNKTAAQIVL RFNIQRGVVV IPKSFNLERI KENFQIFDFS LTEEEMKDIE
     ALNKNVRFVE LLMWRDHPEY PFHDEY
//
